Rising cardiovascular disease incidence is directing more patients into catheter-based coronary interventions, which is reinforcing demand in the bioresorbable vascular scaffold market for devices that can restore vessel patency without leaving a permanent metallic implant behind. In practice, This transitions physician and hospital interest toward treatment options that align with minimally invasive care pathways, shorter recovery expectations, and long-term vessel management, especially for patients who may require future reintervention. As caseloads increase, the appeal of temporary scaffolding that supports the artery during healing and then resorbs becomes more relevant to interventional cardiology decision-making, encouraging market growth through procedure selection and device portfolio evaluation.

Continuous R&D in biodegradable scaffold materials improving safety and long-term patient outcomes

Material innovation is shaping the bioresorbable vascular scaffold market by addressing the issues that have historically limited broader clinical confidence, particularly around scaffold strength, degradation timing, deliverability, and thrombosis risk. Ongoing R&D in polymers, magnesium-based systems, and coating technologies is improving how these devices behave during implantation and throughout resorption, which directly influences physician willingness to adopt newer-generation products. As evidence builds around safer performance profiles and more predictable healing responses, hospitals and specialists are more likely to reconsider bioresorbable platforms as viable alternatives in selected coronary cases, strengthening market development through upgraded product design rather than incremental branding or pricing shifts.

Aging population expanding interventional cardiology procedures and hospital adoption of advanced stents

An aging patient base is increasing the volume of coronary artery disease diagnosis and intervention, creating a larger procedural funnel for the bioresorbable vascular scaffold market as hospitals expand interventional cardiology capacity and refresh their stent offerings. Older adults are more likely to present with complex vascular conditions that require revascularization, prompting providers to evaluate advanced devices that balance acute procedural performance with post-procedure vessel function and long-term treatment flexibility. This dynamic influences procurement and clinical adoption by tying scaffold selection to the broader rise in age-related cardiac interventions, contributing to market size growth through hospital purchasing patterns and specialist use in appropriately selected patients.